It has been recently revealed that the drug for diabetes which was under trial by the FDA is not passed for authenticity for now. They are of the view that there is need for more research and data on the drug, before they can approve it. The name of the drug is dapagliflozin and the FDA is of the view that there is need to prove its worth according to safety, before it can be approved.
It has been recently revealed by the drug firms Novartis AG and AstraZeneca Plc that their drugs undergoing trial for late-stage development for curing hypertension and depression have failed to prove their authenticity in the studies. This has also given rise to rumors about what sort of effect this shall tend to have on their sales and profits in the time to come.
Neuroscientists will no longer attempt for new research in mental disorders, states a news report. The leading drug companies like UK-based GlaxoSmithKline (GSK) and AstraZeneca declared that they will not work on the psychiatric medication in the treatments like depression, dysthymia and schizophrenia. This announcement is a setback to millions of people who suffer from such problems.
Renowned drug companies, including UK-based GlaxoSmithKline and AstraZeneca, have announced that they do not intend to research new antidepressant drugs. A majority of senior scientists have warned that the decision will leave the families without hope along with a huge financial impact on society.
An experimental drug, olaparib, manufactured by the AstraZeneca has been found to slow down the succession of the common and deadly form of ovarian cancer in patients who had responded to chemotherapy earlier.
Olaparib belongs to a class of drugs called PARP inhibitors that help in destroying cancer cells by blocking an enzyme important in repairing DNA damage.
It was a long time of seven years that was taken by US and UK to come to a common understanding about the AstraZeneca’s corporation tax.
The drug making firm is of the view that the first challenge was to change the potential transatlantic double taxation in the year 2004 and shall have to pay a huge sum to the US cover for the tax cover of the past ten years.
AstraZeneca, the makers of Brilinta, had to face another setback when their hopes about the approval of the drug were shattered as FDA postponed its approval by another six months.
US regulators have declared the date of 20 July when they will finally decide whether this new heart drug would receive a green signal or not.
New Zealand News
- After Suspected Botulism, CFIA Warns People
- Health Care Education Necessary for the Future of Province: Analysts
- B.C. Government Grants $700,000 for Managing Facial Deformities
- Michelle Shocked delivers hate speech about homosexuality at her gig
- Guess who Justin Bieber got burned by?!! His ex-girlfriend Selena Gomez